Werewolf Therapeutics, Inc. and Ambros Therapeutics, Inc. announced a definitive merger agreement for an all-stock transaction. This merger will create a combined entity focused on advancing Ambros’ neridronate development program for Complex Regional Pain Syndrome Type 1. Upon completion, the merged company will operate as Ambros Therapeutics and trade under the Nasdaq ticker symbol 'AMBX'.
Company Information
Company
Werewolf Therapeutics
Location
200 Talcott Ave, 2nd Floor
Watertown, Massachusetts, United States
About
Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINETM molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in multiple solid tumor types. WTX-330 is in development as a single agent in refractory and/or immunotherapy unresponsive or resistant advanced or metastatic solid tumors and non-Hodgkin lymphoma.
Don't miss Werewolf Therapeutics's next move
Get an email the moment Werewolf Therapeutics makes an acquisition, hires an exec, or expands, usually minutes after it happens.
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired Ambros Therapeutics?
Ambros Therapeutics was acquired by Werewolf Therapeutics, based in Watertown. The deal was reported on August 21, 2026. Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf Therapeutics is publicly traded (HOWL) and operates in Biotechnology.
When did Werewolf Therapeutics acquire Ambros Therapeutics?
Werewolf Therapeutics's acquisition of Ambros Therapeutics was reported on August 21, 2026. Werewolf Therapeutics, Inc. and Ambros Therapeutics, Inc. announced a definitive merger agreement for an all-stock transaction. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Ambros Therapeutics do?
Ambros Therapeutics is a biotech firm focused on developing a non-opioid pain medicine for Complex Regional Pain Syndrome type 1 (CRPS-1). It is privately held, operating in Biotechnology, and is based in Irvine.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
Watertown